Cargando…
Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy
Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers’ prevalence in rheumatic outpatients belonging to Spondyloarthritis, Chronic Arthritis and Connective Tissue Dis...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696870/ https://www.ncbi.nlm.nih.gov/pubmed/33207663 http://dx.doi.org/10.3390/microorganisms8111792 |
_version_ | 1783615503152971776 |
---|---|
author | Canzoni, Marco Marignani, Massimo Sorgi, Maria Laura Begini, Paola Biondo, Michela Ileen Caporuscio, Sara Colonna, Vincenzo Casa, Francesca Della Conigliaro, Paola Marrese, Cinzia Celletti, Eleonora Modesto, Irene Peragallo, Mario Stefano Laganà, Bruno Picchianti-Diamanti, Andrea Rosa, Roberta Di Ferlito, Claudia Salemi, Simonetta D’Amelio, Raffaele Stroffolini, Tommaso |
author_facet | Canzoni, Marco Marignani, Massimo Sorgi, Maria Laura Begini, Paola Biondo, Michela Ileen Caporuscio, Sara Colonna, Vincenzo Casa, Francesca Della Conigliaro, Paola Marrese, Cinzia Celletti, Eleonora Modesto, Irene Peragallo, Mario Stefano Laganà, Bruno Picchianti-Diamanti, Andrea Rosa, Roberta Di Ferlito, Claudia Salemi, Simonetta D’Amelio, Raffaele Stroffolini, Tommaso |
author_sort | Canzoni, Marco |
collection | PubMed |
description | Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers’ prevalence in rheumatic outpatients belonging to Spondyloarthritis, Chronic Arthritis and Connective Tissue Disease diagnostic groups in Italy. The study enrolled 302 subjects, sex ratio (M/F) 0.6, mean age ± standard deviation 57 ± 15 years, 167 (55%) of whom were candidates for immunosuppressive therapy. The Spondyloarthritis group included 146 subjects, Chronic Arthritis 75 and Connective Tissue Disease 83 (two patients had two rheumatic diseases; thus, the sum is 304 instead of 302). Ten subjects (3%) reported previous anti-HBV vaccination and tested positive for anti-HBs alone with a titer still protective (>10 IU/mL). Among the remaining 292 subjects, the prevalence of positivity for HBsAg, isolated anti-HBc, anti-HBc/anti-HBs, and any HBV marker was 2%, 4%, 18%, and 24%, respectively. A total of 26/302 (9%) patients with γ-globulin levels ≤0.7 g/dL were more frequently (p = 0.03455) prescribed immunosuppressive therapy, suggesting a more severe rheumatic disease. A not negligible percentage of rheumatic patients in Italy are at potential risk of HBV reactivation related to immunosuppressive therapy. Before starting treatment, subjects should be tested for HBV markers. Those resulting positive should receive treatment or prophylaxis with Nucleos (t) ides analogue (NUCs) at high barrier of resistance, or pre-emptive therapy, according to the pattern of positive markers. HB vaccination is recommended for those who were never exposed to the virus. |
format | Online Article Text |
id | pubmed-7696870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76968702020-11-29 Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy Canzoni, Marco Marignani, Massimo Sorgi, Maria Laura Begini, Paola Biondo, Michela Ileen Caporuscio, Sara Colonna, Vincenzo Casa, Francesca Della Conigliaro, Paola Marrese, Cinzia Celletti, Eleonora Modesto, Irene Peragallo, Mario Stefano Laganà, Bruno Picchianti-Diamanti, Andrea Rosa, Roberta Di Ferlito, Claudia Salemi, Simonetta D’Amelio, Raffaele Stroffolini, Tommaso Microorganisms Article Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers’ prevalence in rheumatic outpatients belonging to Spondyloarthritis, Chronic Arthritis and Connective Tissue Disease diagnostic groups in Italy. The study enrolled 302 subjects, sex ratio (M/F) 0.6, mean age ± standard deviation 57 ± 15 years, 167 (55%) of whom were candidates for immunosuppressive therapy. The Spondyloarthritis group included 146 subjects, Chronic Arthritis 75 and Connective Tissue Disease 83 (two patients had two rheumatic diseases; thus, the sum is 304 instead of 302). Ten subjects (3%) reported previous anti-HBV vaccination and tested positive for anti-HBs alone with a titer still protective (>10 IU/mL). Among the remaining 292 subjects, the prevalence of positivity for HBsAg, isolated anti-HBc, anti-HBc/anti-HBs, and any HBV marker was 2%, 4%, 18%, and 24%, respectively. A total of 26/302 (9%) patients with γ-globulin levels ≤0.7 g/dL were more frequently (p = 0.03455) prescribed immunosuppressive therapy, suggesting a more severe rheumatic disease. A not negligible percentage of rheumatic patients in Italy are at potential risk of HBV reactivation related to immunosuppressive therapy. Before starting treatment, subjects should be tested for HBV markers. Those resulting positive should receive treatment or prophylaxis with Nucleos (t) ides analogue (NUCs) at high barrier of resistance, or pre-emptive therapy, according to the pattern of positive markers. HB vaccination is recommended for those who were never exposed to the virus. MDPI 2020-11-16 /pmc/articles/PMC7696870/ /pubmed/33207663 http://dx.doi.org/10.3390/microorganisms8111792 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Canzoni, Marco Marignani, Massimo Sorgi, Maria Laura Begini, Paola Biondo, Michela Ileen Caporuscio, Sara Colonna, Vincenzo Casa, Francesca Della Conigliaro, Paola Marrese, Cinzia Celletti, Eleonora Modesto, Irene Peragallo, Mario Stefano Laganà, Bruno Picchianti-Diamanti, Andrea Rosa, Roberta Di Ferlito, Claudia Salemi, Simonetta D’Amelio, Raffaele Stroffolini, Tommaso Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy |
title | Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy |
title_full | Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy |
title_fullStr | Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy |
title_full_unstemmed | Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy |
title_short | Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy |
title_sort | prevalence of hepatitis b virus markers in patients with autoimmune inflammatory rheumatic diseases in italy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696870/ https://www.ncbi.nlm.nih.gov/pubmed/33207663 http://dx.doi.org/10.3390/microorganisms8111792 |
work_keys_str_mv | AT canzonimarco prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT marignanimassimo prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT sorgimarialaura prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT beginipaola prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT biondomichelaileen prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT caporusciosara prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT colonnavincenzo prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT casafrancescadella prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT conigliaropaola prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT marresecinzia prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT cellettieleonora prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT modestoirene prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT peragallomariostefano prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT laganabruno prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT picchiantidiamantiandrea prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT rosarobertadi prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT ferlitoclaudia prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT salemisimonetta prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT damelioraffaele prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly AT stroffolinitommaso prevalenceofhepatitisbvirusmarkersinpatientswithautoimmuneinflammatoryrheumaticdiseasesinitaly |